Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.
作者信息
Mair Maximilian J, Mitterer Manfred, Gattinger Pia, Berger Julia M, Trutschnig Wolfgang, Bathke Arne C, Gansterer Margaretha, Berghoff Anna S, Laengle Severin, Gottmann Lynn, Buratti Thomas, Haslacher Helmuth, Lamm Wolfgang W, Raderer Markus, Tobudic Selma, Fuereder Thorsten, Valenta Rudolf, Fong Dominic, Preusser Matthias
机构信息
Division of Oncology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
Hemato-Oncological Day Hospital Unit, Franz Tappeiner Hospital, Meran/Merano, Italy.
出版信息
Cancer Cell. 2022 May 9;40(5):444-446. doi: 10.1016/j.ccell.2022.04.003. Epub 2022 Apr 12.
Abstract
摘要
相似文献
1
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron.由于奥密克戎毒株，血液系统癌症和实体癌患者中出现了更多的新冠病毒突破性感染病例。
Cancer Cell. 2022 May 9;40(5):444-446. doi: 10.1016/j.ccell.2022.04.003. Epub 2022 Apr 12.
2
SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.Omicron BA.1 变异株突破感染同源第三剂 Comirnaty® COVID-19 疫苗后的养老院居民：寻找保护相关因素。
J Med Virol. 2022 Sep;94(9):4216-4223. doi: 10.1002/jmv.27867. Epub 2022 May 25.
3
Levels of SARS-CoV-2 antibodies among fully vaccinated individuals with Delta or Omicron variant breakthrough infections.完全接种疫苗的德尔塔或奥密克戎变异突破感染个体中的 SARS-CoV-2 抗体水平。
Nat Commun. 2022 Aug 1;13(1):4466. doi: 10.1038/s41467-022-32254-8.
4
Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.评估中国广东省肇庆市未接种疫苗的个体和奥密克戎 BA.2 感染疫苗接种者针对 SARS-CoV-2 的抗体反应。
Virol J. 2022 Nov 25;19(1):197. doi: 10.1186/s12985-022-01912-0.
5
Anti-spike protein antibody titer at the time of breakthrough infection of SARS-CoV-2 omicron.奥密克戎突破感染时的抗刺突蛋白抗体滴度。
J Infect Chemother. 2022 Jul;28(7):1015-1017. doi: 10.1016/j.jiac.2022.03.021. Epub 2022 Apr 1.
6
Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.奥密克戎 BA.5 对先前感染奥密克戎 BA.1/BA.2 后接种疫苗人群的中和作用。
Emerg Infect Dis. 2022 Dec;28(12):2575-2577. doi: 10.3201/eid2812.221304. Epub 2022 Nov 8.
7
Neutralising activity and antibody titre in 10 patients with breakthrough infections of the SARS-CoV-2 Omicron variant in Japan.在日本，10 名感染 SARS-CoV-2 奥密克戎变异株突破性感染的患者的中和活性和抗体滴度。
J Infect Chemother. 2022 Sep;28(9):1340-1343. doi: 10.1016/j.jiac.2022.04.018. Epub 2022 Apr 22.
8
Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy.在意大利 Delta 和奥密克戎变异株流行期间，接受疾病修正治疗的多发性硬化症患者在感染 COVID-19 后突破性感染 SARS-CoV-2。
EBioMedicine. 2022 Jun;80:104042. doi: 10.1016/j.ebiom.2022.104042. Epub 2022 May 5.
9
Viral Load Dynamics in SARS-CoV-2 Omicron Breakthrough Infections.奥密克戎突破性感染中的病毒载量动态。
J Infect Dis. 2022 Nov 11;226(10):1721-1725. doi: 10.1093/infdis/jiac290.
10
Neutralizing antibody levels against SARS-CoV-2 variants of concern Delta and Omicron in vaccine breakthrough-infected blood donors.疫苗突破性感染献血者中针对新冠病毒关切变异株德尔塔和奥密克戎的中和抗体水平。
Transfusion. 2022 Jun;62(6):1171-1176. doi: 10.1111/trf.16887. Epub 2022 Apr 20.
引用本文的文献
1
Impact of Cancer Subtype and Cancer Therapy Exposures on SARS-CoV-2 Outcomes in the Omicron and Subvariant Era.癌症亚型和癌症治疗暴露对奥密克戎及其亚型流行时代严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染结局的影响
Cancer Med. 2025 Jul;14(14):e71082. doi: 10.1002/cam4.71082.
2
COVALENCE STUDY: Immunogenicity and Reactogenicity of a COVID-19 mRNA Vaccine in an Open-Label Cohort of Long-Survivor Patients with Metastatic Lung Cancer.共价研究：新冠病毒mRNA疫苗在转移性肺癌长期存活患者开放标签队列中的免疫原性和反应原性
Vaccines (Basel). 2025 Mar 5;13(3):273. doi: 10.3390/vaccines13030273.
3
[Single-center study of COVID-19 in patients with chronic lymphocytic leukemia].慢性淋巴细胞白血病患者新冠病毒病的单中心研究
Zhonghua Xue Ye Xue Za Zhi. 2024 Oct 14;45(10):923-930. doi: 10.3760/cma.j.cn121090-20240621-00230.
4
Inactivated vaccine dosage and serum IgG levels correlate with persistent COVID-19 infections in hematologic malignancy patients during the Omicron Surge in China.在奥密克戎变异株流行期间，灭活疫苗剂量和血清 IgG 水平与中国血液恶性肿瘤患者持续性 COVID-19 感染相关。
BMC Infect Dis. 2024 Oct 11;24(1):1141. doi: 10.1186/s12879-024-10063-2.
5
COVID-19 in Lung Transplant Recipients: A Report on 10 Recent Cases.肺移植受者中的 COVID-19：10 例近期病例报告。
Viruses. 2024 Apr 29;16(5):709. doi: 10.3390/v16050709.
6
Safety and Immunogenicity of the Convacell Recombinant N Protein COVID-19 Vaccine.康瓦塞尔重组N蛋白新冠疫苗的安全性和免疫原性
Vaccines (Basel). 2024 Jan 19;12(1):100. doi: 10.3390/vaccines12010100.
7
mRNA vaccines against SARS-CoV-2 induce divergent antigen-specific T-cell responses in patients with lung cancer.mRNA 疫苗针对 SARS-CoV-2 可诱导肺癌患者产生不同的抗原特异性 T 细胞反应。
J Immunother Cancer. 2024 Jan 4;12(1):e007922. doi: 10.1136/jitc-2023-007922.
8
Clinical characteristics of SARS-CoV-2 Omicron variant infection in children with acute leukemia.奥密克戎变异株感染儿童急性白血病的临床特征。
Ann Hematol. 2024 Mar;103(3):729-736. doi: 10.1007/s00277-023-05593-9. Epub 2023 Dec 28.
9
COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.癌症患者和接受 HSCT 或 CAR-T 治疗患者的 COVID-19 疫苗接种：免疫反应、真实世界疗效以及对未来的影响。
J Infect Dis. 2023 Aug 4;228(Suppl 1):S55-S69. doi: 10.1093/infdis/jiad174.
10
Updated COVID-19 clearance time among patients with cancer in the Delta and Omicron waves.奥密克戎变异株流行期间与德尔塔变异株流行期间癌症患者的新冠病毒清除时间比较。
Cancer Med. 2023 Aug;12(16):16869-16875. doi: 10.1002/cam4.6311. Epub 2023 Jul 1.
本文引用的文献
1
Vaccine based on folded receptor binding domain-PreS fusion protein with potential to induce sterilizing immunity to SARS-CoV-2 variants.基于折叠的受体结合域-PreS 融合蛋白的疫苗，具有诱导对 SARS-CoV-2 变体产生有效免疫力的潜力。
Allergy. 2022 Aug;77(8):2431-2445. doi: 10.1111/all.15305. Epub 2022 Apr 15.
2
Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients.免疫功能低下患者的 COVID-19 mRNA 疫苗针对关注变种的体液反应。
JAMA Oncol. 2022 May 1;8(5):e220446. doi: 10.1001/jamaoncol.2022.0446. Epub 2022 May 19.
3
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant.Covid-19 疫苗对奥密克戎（B.1.1.529）变异株的有效性。
N Engl J Med. 2022 Apr 21;386(16):1532-1546. doi: 10.1056/NEJMoa2119451. Epub 2022 Mar 2.
4
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort study.血液肿瘤患者和医护人员接种 SARS-CoV-2 疫苗第三针：免疫应答和不良事件——一项回顾性队列研究。
Eur J Cancer. 2022 Apr;165:184-194. doi: 10.1016/j.ejca.2022.01.019. Epub 2022 Feb 7.
5
Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave.奥密克戎毒株流行期间新冠病毒病对癌症患者病死率的影响
Cancer Cell. 2022 Apr 11;40(4):343-345. doi: 10.1016/j.ccell.2022.02.012. Epub 2022 Feb 22.
6
Omicron: A SARS-CoV-2 variant of real concern.奥密克戎：一种令人高度关注的严重急性呼吸综合征冠状病毒2变体。
Allergy. 2022 May;77(5):1616-1620. doi: 10.1111/all.15264. Epub 2022 Feb 28.
7
Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.癌症患者接种第三剂新冠疫苗后的奥密克戎中和抗体
Lancet. 2022 Mar 5;399(10328):905-907. doi: 10.1016/S0140-6736(22)00147-7. Epub 2022 Jan 25.
8
Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa.BNT162b2疫苗在南非针对奥密克戎变异株的有效性
N Engl J Med. 2022 Feb 3;386(5):494-496. doi: 10.1056/NEJMc2119270. Epub 2021 Dec 29.
9
Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry.癌症患者 COVID-19 死亡率的时间依赖性：OnCovid 登记处的最新分析。
JAMA Oncol. 2022 Jan 1;8(1):114-122. doi: 10.1001/jamaoncol.2021.6199.
10
Seroconversion rate after vaccination against COVID-19 in patients with cancer-a systematic review.接种 COVID-19 疫苗后癌症患者的血清转化率：系统评价。
Ann Oncol. 2022 Feb;33(2):158-168. doi: 10.1016/j.annonc.2021.10.014. Epub 2021 Oct 28.
Zotero 插件